Theriva Biologics

Historical price data

Theriva Biologics is advancing a differentiated oncolytic virus platform engineered for systemic intravenous delivery, a key limitation of earlier therapies. Its lead candidate, VCN-01, has demonstrated promising clinical activity in metastatic pancreatic ductal adenocarcinoma (PDAC) and is positioned for a pivotal Phase 3 trial following a positive End-of-Phase 2 FDA meeting. The company's strategy focuses on leveraging its stroma-degrading and Albumin Shield™ technologies to treat difficult-to-treat solid tumors, both as monotherapy and in combination with chemotherapy and immunotherapy.

Engineered oncolytic adenovirus platform designed for systemic intravenous delivery, featuring tumor-selective replication, localized expression of hyaluronidase (PH20) to degrade the tumor stroma, and Albumin Shield™ technology to evade neutralizing antibodies.

Theriva's primary differentiator is systemic IV delivery, setting it apart from approved intratumoral viruses like Amgen's Imlygic. It competes in the next-generation oncolytic virus segment with companies like Replimune, but its specific focus on enzymatic stroma degradation and antibody evasion provides a unique technological niche.